The New Era of Neuromyelitis Optica Spectrum Disorder: Advances in Diagnosis and Treatment

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

The program is supported by independent educational grants from Alexion Pharmaceuticals and Genentech.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
• Nurses — 1.0 Contact Hours (0.5 in the area of pharmacology)
• Pharmacists — maximum of 1.0 ACPE Credit Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intented for neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to the diagnosis and management of patients with neuromyelitis optica spectrum disorder.

Program Overview

The educational goal of this activity is to provide clinicians with important information on ensuring an accurate diagnosis of NMOSD and updates on novel treatment options for patients with the disease.

Description

This activity reviews evidence-based recommendations, challenges, and advances in the diagnosis and treatment of NMO spectrum disorder. (A recording of live events that occurred on 1/14/2021 and on 1/19/2021.)

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Define symptoms of NMOSD and common diseases that mimic NMOSD
• Summarize consensus diagnostic criteria for NMOSD
• Review diagnostic testing methods for NMOSD
• Employ team-based approaches to the early and accurate diagnosis of NMOSD
• Review novel treatment options for NMOSD
• Apply evidence-based approaches to personalizing treatment for patients with NMOSD

Faculty

Program Chair and Presenter

Faculty (Content Development)

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team

Physician Continuing Medical Education

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (0.5 in the area of pharmacology).

Pharmacists

This knowledge-based activity, UAN JA4008165-9999-21-002-H01-P, qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.

Disclosures of Conflicts of Interest

Faculty Disclosures

The following faculty report that they have relevant financial relationships to disclose:

Brian G. Weinshenker, MD, FRCP(C)

• Royalty: Hospices Civils de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Oxford University, RSR Limited
• Receipt of Intellectual Property Rights/Patent Holder: Patent for use of NMO-IgG as diagnostic test for neuromyelitis optica spectrum disorder
• Consulting Fee: Chugai/Roche/Genentech (satralizumab clinical trial); Mitsubishi Tanabe (trial design)
• Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Its Agent: Genentech
• Other: Chair for attack adjudication committee for Alexion and MedImmune/Viela Bio

Marcelo Matiello, MD

• Consulting Fee: Viela Bio

Activity Staff Disclosures

June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive credit, participants must read the CME/CE information and faculty disclosures, complete the pre-test questions, view the activity, and complete the post-test and evaluation form. Statements of Credit are awarded upon successful completion of the post-test, with a passing score of 65%, and evaluation form.

Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

During this presentation, Dr. Weinshenker may reference rituximab, tocilizumab, and other immunosuppressant medications to treat neuromyelitis optica spectrum disorder.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For CME/CE questions please contact Catamount Medical Education at info@catmeded.com